Biogen

BioNTech US Inc, based in Cambridge, MA, is a pioneering global immunotherapy company that focuses on developing innovative treatments aimed at combatting cancer, infectious diseases, and other serious health conditions. With its origins in Mainz, Germany, the company leverages a robust international network and a strong commitment to research and development to advance next-generation immunotherapies. Driven by scientific rigor and operational excellence, BioNTech is dedicated to unlocking the full potential of the immune system and enhancing the health of individuals worldwide. The company continually expands its global manufacturing capabilities to ensure equitable access to its innovative therapies. Generated from the website

Nitto Denko Avecia Inc., located in Cambridge, MA, is a leading provider of comprehensive oligonucleotide solutions, offering a full range of services from preclinical manufacturing to drug substance manufacturing, supported by 25 years of industry experience. With a dedicated team of over 500 professionals and 2 cGMP facilities, the company is committed to advancing drug development programs with innovative processes and expert quality control. As a trusted partner in the pharmaceutical sector, Nitto Avecia combines the strengths of Nitto Avecia and Nitto Avecia Pharma Services to support clients throughout every stage of drug development. Their capabilities include analytical development, process optimization, and stability testing, ensuring a robust and efficient approach to oligonucleotide manufacturing. Generated from the website

Aastrom Biosciences develops products for the repair or regeneration of multiple human tissues, based on its proprietary Tissue Repair Cell adult stem cell technology. Aastrom's TRC products contain large numbers of stromal, stem and progenitor cells that are produced from a small amount of bone marrow cells originating from patients. Its patented AastromReplicell system, an industry-unique automated cell product manufacturing platform, was developed for the production of standardized, patient-specific TRC products. TRC products have been used safely in humans as a substitute for bone marrow stem cells and are currently in clinical trials for bone grafting and blood vessel regeneration applications. Aastrom Biosciences is located in Ann Arbor, Mich., and trades on the NASDAQ under the symbol ASTM.